Drug
BI 6727 clinical trials
Also written Volasertib and BI 6727.
- studies test it
- 24
- open now
- 0
- in phase 3
- 1
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2016 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 6
Boehringer Ingelheim (18) · University of Ulm (1) · Massachusetts General Hospital (1) · Yale University (1) · University of Alberta (1) · Northwestern University (1) · Anne Beaven, MD (1)
Often tested with
Tested in the same studies.
Azacitidine (2) · Cytarabine (1) · Itraconazole (1) · Afatinib (1) · Nintedanib (1) · Decitabine (1) · Belinostat (1) · Romidepsin (1)
Studies
Open first, then newest update. How each study uses BI 6727 is read from its arms, and is right about nine times in ten.
Testing it · 24
- Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid LeukaemiaCompletedPhase 2Boehringer IngelheimNCT00804856Written as Volasertib
- BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid TumoursCompletedPhase 1Boehringer IngelheimNCT02273388Written as BI 6727
- Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various TumoursCompletedPhase 1Boehringer IngelheimNCT01772563Written as volasertib
- Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)CompletedPhase 3Boehringer IngelheimNCT01721876Written as Volasertib
- Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid CancersCompletedPhase 1Boehringer IngelheimNCT00969553Written as BI 6727
- Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMMLTerminatedPhase 1Boehringer IngelheimNCT01957644Written as Volasertib
- An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid TumoursCompletedPhase 1Boehringer IngelheimNCT01206816Written as BI 6727 + BIBW 2992
- BI 6727 (Volasertib) Human ADME Trial in Various Solid TumoursCompletedPhase 1Boehringer IngelheimNCT01145885Written as BI 6727
- BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid TumourCompletedPhase 1Boehringer IngelheimNCT00969761Written as BI-6727
- Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedPhase 1Boehringer IngelheimNCT02003573Written as volasertib iv infusion
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is KnownCompletedPhase 1Boehringer IngelheimNCT01971476Written as volasertib
- Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaCompletedPhase 1Boehringer IngelheimNCT02201329Written as Volasertib
- Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)CompletedPhase 1Boehringer IngelheimNCT01662505Written as Volasertib
- Combination of BI6727 (Volasertib) and BIBF1120 in Solid TumorsCompletedPhase 1Boehringer IngelheimNCT01022853Written as BI 6727
- Volasertib Combined With Induction Chemotherapy in Acute Myeloid LeukemiaWithdrawnPhase 1Massachusetts General HospitalNCT02905994Written as Volasertib
- Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedPhase 2University of UlmNCT02198482Written as Volasertib
- Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnPhase 1Yale UniversityNCT02875002Written as volasertib
- Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial CancerCompletedPhase 2Boehringer IngelheimNCT01023958Written as BI 6727, IV infusion
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaWithdrawnPhase 1University of AlbertaNCT02527174Written as Volasertib
- A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy FailedWithdrawnPhase 1Boehringer IngelheimNCT02722135Written as Volasertib
See all 24 studies that test BI 6727 →